Lawrence A. Leiter

MDCM, FRCPC, FACP, FACE, FAHA

Investigator

Biography

Please note: Dr. Leiter is not taking any summer students.

Dr. Lawrence A. Leiter is Director of the Lipid Clinic, Associate Director of the Clinical Nutrition and Risk Factor Modification Centre and an Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital in Toronto.  From 2000-2010, he was Head of the Division of Endocrinology and Metabolism. He is a Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto.

Dr. Leiter has several research interests including clinical trials on the prevention of atherosclerosis, especially in diabetes, and the dietary and pharmacologic treatment of diabetes mellitus, hyperlipidemia, hypertension, and obesity. He has over 750 publications in peer-reviewed journals. He was an investigator in many of the landmark diabetes trials including the Diabetes Control and Complications Trial (DCCT), Action to Control Cardiovascular Risk in Diabetes (ACCORD), and Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) and is on the Steering Committees of many ongoing outcome trials in both the diabetes and lipid areas. In 2018, 2019, and 2020 he was a Clarivate Analytics Top 1% Highly Cited Researcher

Dr. Leiter is a past President of the Canadian Society of Endocrinology & Metabolism (CSEM) and a past Chair of the Clinical and Scientific Section of the Canadian Diabetes Association (CDA). He has been involved in many national and international committees and consensus conferences including those of the International Diabetes Federation, CDA, Canadian Hypertension Education Program (CHEP), Canadian Cardiovascular Society (Dyslipidemia), and Obesity Canada.

For his work, he has received a number of awards including the CDA Frederick G. Banting Award and the American Diabetes Association Charles H Best Award (awarded to DCCT investigators), both for Distinguished Service. In 2016, Dr. Leiter received the Canadian Diabetes Association Long Term Achievement Award for Research and the Canadian Society of Endocrinology’s Robert Volpe Distinguished Service Award. He was also the inaugural winner of the St. Michael’s Hospital Complete Physician Award in 2009.  In 2019 was elected as a Fellow of the Canadian Academy of Health Sciences

Recent Publications

  1. Pollack, R, Raz, I, Wiviott, SD, Goodrich, EL, Murphy, SA, Yanuv, I et al.. Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58. Diabetes Care. 2022; :. doi: 10.2337/dc22-1318. PubMed PMID:36399721 .
  2. Das Pradhan, A, Glynn, RJ, Fruchart, JC, MacFadyen, JG, Zaharris, ES, Everett, BM et al.. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med. 2022;387 (21):1923-1934. doi: 10.1056/NEJMoa2210645. PubMed PMID:36342113 .
  3. Connelly, KA, Mazer, CD, Puar, P, Teoh, H, Wang, CH, Mason, T et al.. Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial. Circulation. 2022; :. doi: 10.1161/CIRCULATIONAHA.122.062769. PubMed PMID:36335517 .
  4. Ray, KK, Raal, FJ, Kallend, DG, Jaros, MJ, Koenig, W, Leiter, LA et al.. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2022; :. doi: 10.1093/eurheartj/ehac594. PubMed PMID:36331326 .
  5. Ray, KK, Kallend, D, Leiter, LA, Raal, FJ, Koenig, W, Jaros, MJ et al.. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022; :. doi: 10.1093/eurheartj/ehac615. PubMed PMID:36331315 .
  6. Jenkins, DJA, Chiavaroli, L, Mirrahimi, A, Mitchell, S, Faulkner, D, Sahye-Pudaruth, S et al.. Glycemic Index Versus Wheat Fiber on Arterial Wall Damage in Diabetes: A Randomized Controlled Trial. Diabetes Care. 2022;45 (12):2862-2870. doi: 10.2337/dc22-1028. PubMed PMID:36326712 .
  7. Abtan, J, Bhatt, DL, Elbez, Y, Ducrocq, G, Goto, S, Smith, SC Jr et al.. External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry. Int J Cardiol. 2022; :. doi: 10.1016/j.ijcard.2022.10.132. PubMed PMID:36270493 .
  8. Qi, X, Chiavaroli, L, Lee, D, Ayoub-Charette, S, Khan, TA, Au-Yeung, F et al.. Effect of Important Food Sources of Fructose-Containing Sugars on Inflammatory Biomarkers: A Systematic Review and Meta-Analysis of Controlled Feeding Trials. Nutrients. 2022;14 (19):. doi: 10.3390/nu14193986. PubMed PMID:36235639 PubMed Central PMC9572084.
  9. Jenkins, DJA, Jones, PJH, Abdullah, MMH, Lamarche, B, Faulkner, D, Patel, D et al.. Low-carbohydrate vegan diets in diabetes for weight loss and sustainability: a randomized controlled trial. Am J Clin Nutr. 2022; :. doi: 10.1093/ajcn/nqac203. PubMed PMID:36156115 .
  10. Branch, KRH, Dagenais, GR, Avezum, A, Basile, J, Conget, I, Cushman, WC et al.. Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial. Eur J Heart Fail. 2022;24 (10):1805-1812. doi: 10.1002/ejhf.2670. PubMed PMID:36073143 .
Search PubMed

Affiliations & Other Activities

  • Director, Lipid Clinic, St. Michael’s Hospital
  • Associate Director, Clinical Nutrition and Risk Factor Modification Centre, St. Michael’s Hospital
  • Professor, Departments of Medicine and Nutritional Sciences, University of Toronto